About this trial
Mitral stenosis (MS) is a heavily symptomatic valvular heart disease. Common causes of MS included chronic rheumatic heart disease (CRHD) and mitral annular calcification (MAC). Current guideline recommends percutaneous balloon mitral valvuloplasty (PBMV) being the first line intervention for rheumatic MS with favorable anatomy. However, severely calcified mitral valve (i.e. those with Wilkins scores\>8) makes the mitral valve non-pliable and carries high risk of severe mitral regurgitation (MR) (4-19%) with conventional balloon valvuloplasty. MAC is an increasingly recognized disease associated with atherosclerotic risk factors, and a well-recognized valve morphology that responses poorly with PBMV. Besides, conventional open-heart surgery for MAC-associated mitral valve dysfunction carries high mortality. Transcatheter mitral valve replacement with valve-in-MAC has become an alternative in treating these patients. However, valve-in-MAC is not always feasible and still carries operative and 30-day mortality.
Intravascular lithotripsy is an approved adjunct interventional therapy in treating calcified lesions to facilitate stenotic lesion opening in peripheral vascular disease and coronary artery disease. The off-label use of current peripheral lithotripsy balloon in mitral valve as a compassionate treatment or as an adjunct treatment before mitral balloon valvuloplasty and transcatheter mitral valve replacement has been reported with success . A possible mechanism is that lithotripsy preferentially impacts hard tissue, disrupts calcium, and leaves soft tissue undisturbed, improving valve pliability, preventing leaflet damage, and making subsequent valvuloplasty safer. However, the off-label use of multiple peripheral lithotripsy balloons in mitral valve is technically complicated.
SmartWave balloon was specifically designed lithotripsy balloon for calcified aortic stenosis. This first-in-human study aims to apply the SmartWave lithotripsy balloon in treating calcified mitral stenosis due to MAC or severely calcified rheumatic mitral valve.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age >18 and
Able to give procedure and study consent and
Severe symptomatic mitral stenosis (MVA <1.5cm² derived by 3D planimetry or continuity equation or pressure half time) and
Presence of mitral annular calcification or
Disqualifiers
Baseline > moderate MR
Intracardiac thrombus as visualized by TEE
Pregnant patients. Female patients of childbearing potential must have a negative pregnancy test (per site standard test) within 7 days prior to index procedure.
Active infection with bacteremia
Trial design
Single group
Treatments tested in this trial
SmartWave Lithotripsy balloon
Devicentravascular lithotripsy is an approved adjunct interventional therapy in treating calcified lesions to facilitate stenotic lesion opening in peripheral vascular disease and coronary artery disease. The off-label use of current peripheral lithotripsy balloon in mitral valve as a compassionate treatment or as an adjunct treatment before mitral balloon valvuloplasty and transcatheter mitral valve replacement has been reported with success . A possible mechanism is that lithotripsy preferentially impacts hard tissue, disrupts calcium, and leaves soft tissue undisturbed, improving valve pliability, preventing leaflet damage, and making subsequent valvuloplasty safer.
Treatment groups
Trial outcomes
Primary outcomes
Improvement in mitral valve area
Immediate and sustained improvement in mitral valve area (MVA \>1.5cm\^2) without significant worsening of MR (\> moderate)
Absence of peri-procedural complication
Absence of peri-procedural complication (death, stroke, myocardial infarction, cardiac tamponade, conversion to open heart) defined according to the Mitral Valve Academic Research Consortium
Secondary outcomes
Hemodynamic changes
Invasive haemodyanmic changes after each lithotripsy cycle
Mitral valve calcification level
Baseline and post-procedural mitral valve calcium distribution and volume determined by computed tomography
Symptom status change (New York Heart Aassociation functional class)
Symptom status change assessed by New York Heart Aassociation functional class
Symptom status change (By Kansas City Cardiomyopathy Questionnaire-12)
Symptom status change assessed by Kansas City Cardiomyopathy Questionnaire-12
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Prince of Wales Hospital, Shatin, Hong Kong
Lead sponsor
Peijia Medical Technology (Suzhou) Co., Ltd.
Collaborator